within Pharmacolibrary.Drugs.ATC.N;

model N06AX24
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.000525,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.308,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 18.0,            
    Vdp             = 0.168,
    k12             = 69.7,
    k21             = 69.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vilazodone is an antidepressant medication that acts as a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist. It is approved for the treatment of major depressive disorder (MDD) in adults and is currently marketed in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sartini, I, et al., &amp; Giorgi, M (2019). Effect of feeding on the pharmacokinetics of vilazodone in dogs. <i>Research in veterinary science</i> 125 309–314. DOI:<a href=\"https://doi.org/10.1016/j.rvsc.2019.07.013\">10.1016/j.rvsc.2019.07.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31351201/\">https://pubmed.ncbi.nlm.nih.gov/31351201</a></p></li><li><p>Boinpally, R, et al., &amp; Periclou, A (2015). Pharmacokinetics and Safety of Vilazodone in Hepatic Impairment. <i>American journal of therapeutics</i> 22(4) 269–277. DOI:<a href=\"https://doi.org/10.1097/MJT.0000000000000173\">10.1097/MJT.0000000000000173</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25474324/\">https://pubmed.ncbi.nlm.nih.gov/25474324</a></p></li><li><p>Boinpally, R, et al., &amp; Edwards, J (2013). Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. <i>Clinical drug investigation</i> 33(3) 199–206. DOI:<a href=\"https://doi.org/10.1007/s40261-013-0061-5\">10.1007/s40261-013-0061-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23417352/\">https://pubmed.ncbi.nlm.nih.gov/23417352</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX24;
